Literature DB >> 2322540

24-homologated 1,25-dihydroxyvitamin D3 compounds: separation of calcium and cell differentiation activities.

K Perlman1, A Kutner, J Prahl, C Smith, M Inaba, H K Schnoes, H F DeLuca.   

Abstract

A series of 24-homologated 1,25-dihydroxyvitamin D3 compounds have been chemically synthesized and studied with regard to their activity in inducing differentiation of human promyelocyte HL-60 cells to monocytes and in calcium mobilizing activity in vitamin D deficient rats. Homologation of 1,25-dihydroxyvitamin D3 or its delta 22 analogue by one or two carbons increases by 10-fold and three-carbon homologation reduces by half the activity in causing differentiation of HL-60. On the other hand, homologation causes a substantial decrease in in vivo calcium mobilization activity. The addition of each carbon at the 24-position decreases binding to the HL-60 receptor or rat intestinal receptor by 5-10-fold so that binding affinity of the trihomo compound for the receptors is 130 times less that of 1,25-dihydroxyvitamin D3. Thus, binding affinity for the receptor cannot account for the preferential activity of the 24-homologated compounds in inducing cell differentiation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2322540     DOI: 10.1021/bi00453a026

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

1.  A potent analog of 1alpha,25-dihydroxyvitamin D3 selectively induces bone formation.

Authors:  Nirupama K Shevde; Lori A Plum; Margaret Clagett-Dame; Hironori Yamamoto; J Wesley Pike; Hector F DeLuca
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-08       Impact factor: 11.205

2.  Overproduction of rat 1,25-dihydroxyvitamin D3 receptor in insect cells using the baculovirus expression system.

Authors:  T K Ross; J M Prahl; H F DeLuca
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-01       Impact factor: 11.205

3.  The rationale for deltanoids in therapy for myeloid leukemia: role of KSR-MAPK-C/EBP pathway.

Authors:  George P Studzinski; Xuening Wang; Yan Ji; Qing Wang; Yingyu Zhang; Andrzej Kutner; Jonathan S Harrison
Journal:  J Steroid Biochem Mol Biol       Date:  2005-07-25       Impact factor: 4.292

4.  Biologically active noncalcemic analogs of 1alpha,25-dihydroxyvitamin D with an abbreviated side chain containing no hydroxyl.

Authors:  Lori A Plum; Jean M Prahl; Xiaohong Ma; Rafal R Sicinski; Sumithra Gowlugari; Margaret Clagett-Dame; Hector F DeLuca
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-26       Impact factor: 11.205

5.  Effects of analogs of 1,25(OH)2 vitamin D3 on the proliferation and differentiation of the human chronic myelogenous leukemia cell line, RWLeu-4.

Authors:  J W Clark; M R Posner; J M Marsella; A Santos; M Uskokovic; C Eil; S R Lasky
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

6.  Partial prevention of active Heymann nephritis by 1 alpha, 25 dihydroxyvitamin D3.

Authors:  D D Branisteanu; P Leenaerts; B van Damme; R Bouillon
Journal:  Clin Exp Immunol       Date:  1993-12       Impact factor: 4.330

7.  Calcium regulating activity of 24a-homo-24,24-difluoro-1 alpha,25-dihydroxyvitamin D3 and 26,27-dimethyl-24,24-difluoro-1 alpha,25-dihydroxyvitamin D3.

Authors:  M Harada; T Miyahara; M Miyata; H Komiyama; A Sugure; Y Ikemoto; S Kondo; T Takamura; S Higuchi; S Otomo
Journal:  Calcif Tissue Int       Date:  1993-11       Impact factor: 4.333

8.  Antiproliferative Activity of Double Point Modified Analogs of 1,25-Dihydroxyvitamin D₂ Against Human Malignant Melanoma Cell Lines.

Authors:  Anna Piotrowska; Justyna Wierzbicka; Sharmin Nadkarni; Geoffrey Brown; Andrzej Kutner; Michał A Żmijewski
Journal:  Int J Mol Sci       Date:  2016-01-08       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.